UPDATE: Oppenheimer Maintains Outperform On Medicines Co., Raises Target To $60 As Firm Notes Positive Inclisiran Data 'significantly de-risk ORION-9&10 data to read-out sequentially in late 3Q'
Benzinga_Newsdesk